Shield Therapeutics plc has emerged from a rollercoaster ride in 2018 and is now in "good shape", with a cash runway that extends into 2020 and a US PDUFA date for its lead product, Feraccru (ferric maltol) in mid-2019. The company is now evaluating US commercialization options for Feraccru, it announced on Jan. 24.
Shield Therapeutics Looking At US Options For Feraccru
The UK biotech has revised its business strategy over the past year, and Shield's CEO believes the company's lead product for iron deficiency is now well positioned to compete with current and potential entrants in the therapeutic sector.
